Testing patient's own lung stem cells for ILD
Part of Lungs & breathing clinical trials.
This study tests whether a patient's own lung stem cells can be used to repair damaged lungs in people with interstitial lung disease. It is an early-stage trial to see if the treatment is safe and may help improve breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 75 years old.
- You have been diagnosed with interstitial lung disease (ILD) like IPF or ILD related to a connective tissue disease.
- Your lung function test (DLCO) is between 30% and 80% of the predicted normal value.
- You are not pregnant, breastfeeding, or planning pregnancy in the next year.
- You do not have active cancer or a history of cancer.
- You have tested negative for HIV, hepatitis B, hepatitis C, and syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks how safe a lung biopsy (a small sample taken with a needle) is for people with interstitial lung disease, a condition that causes scarring in the lungs. The goal is to see if the biopsy can be done with fewer risks when guided by ultrasound.
This study is testing a new way to speed up the diagnosis of interstitial lung disease (a group of lung scarring conditions). If you have symptoms or scan findings that suggest ILD but haven't been fully diagnosed yet, this trial may help you get a faster, clearer answer.
This study looks at how to find and treat fibrotic interstitial lung disease (a condition where lung tissue becomes scarred and stiff) as early as possible. It may help people with this type of lung disease get better care.
This early-stage trial tests a new treatment using extracts from human umbilical cord stem cells, given by inhalation, to see if it is safe and can help patients with interstitial lung disease (a condition where lung tissue becomes scarred and stiff). The study will measure whether this approach reduces symptoms and improves how well your lungs work.
This trial tests a new medicine called NCR101 for people with interstitial lung disease (a lung condition that causes scarring). It aims to see if the drug is safe and helps slow the disease. You may be able to join if your current treatments are stable.
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Hear when a new Interstitial Lung Disease (ILD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.